A short discussion about the SARS-CoV-2 mRNA-1273 vaccine

The COVID-19 global pandemic has prompted accelerated vaccine development efforts. This perspective discusses the importance of SARS-CoV-2 vaccine candidates’ recruitment of cellular T-cell immunity and encourages industry to increasingly investigate and publish parameters related to cellular immuni...

Descripción completa

Detalles Bibliográficos
Autores principales: Oronsky, Bryan, Gruber, Harry E., Reiners, Wendy, Reid, Tony R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825869/
https://www.ncbi.nlm.nih.gov/pubmed/33493690
http://dx.doi.org/10.1016/j.ijid.2021.01.048
_version_ 1783640408930123776
author Oronsky, Bryan
Gruber, Harry E.
Reiners, Wendy
Reid, Tony R.
author_facet Oronsky, Bryan
Gruber, Harry E.
Reiners, Wendy
Reid, Tony R.
author_sort Oronsky, Bryan
collection PubMed
description The COVID-19 global pandemic has prompted accelerated vaccine development efforts. This perspective discusses the importance of SARS-CoV-2 vaccine candidates’ recruitment of cellular T-cell immunity and encourages industry to increasingly investigate and publish parameters related to cellular immunity in their research reports.
format Online
Article
Text
id pubmed-7825869
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-78258692021-01-25 A short discussion about the SARS-CoV-2 mRNA-1273 vaccine Oronsky, Bryan Gruber, Harry E. Reiners, Wendy Reid, Tony R. Int J Infect Dis Perspective The COVID-19 global pandemic has prompted accelerated vaccine development efforts. This perspective discusses the importance of SARS-CoV-2 vaccine candidates’ recruitment of cellular T-cell immunity and encourages industry to increasingly investigate and publish parameters related to cellular immunity in their research reports. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-03 2021-01-23 /pmc/articles/PMC7825869/ /pubmed/33493690 http://dx.doi.org/10.1016/j.ijid.2021.01.048 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Perspective
Oronsky, Bryan
Gruber, Harry E.
Reiners, Wendy
Reid, Tony R.
A short discussion about the SARS-CoV-2 mRNA-1273 vaccine
title A short discussion about the SARS-CoV-2 mRNA-1273 vaccine
title_full A short discussion about the SARS-CoV-2 mRNA-1273 vaccine
title_fullStr A short discussion about the SARS-CoV-2 mRNA-1273 vaccine
title_full_unstemmed A short discussion about the SARS-CoV-2 mRNA-1273 vaccine
title_short A short discussion about the SARS-CoV-2 mRNA-1273 vaccine
title_sort short discussion about the sars-cov-2 mrna-1273 vaccine
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825869/
https://www.ncbi.nlm.nih.gov/pubmed/33493690
http://dx.doi.org/10.1016/j.ijid.2021.01.048
work_keys_str_mv AT oronskybryan ashortdiscussionaboutthesarscov2mrna1273vaccine
AT gruberharrye ashortdiscussionaboutthesarscov2mrna1273vaccine
AT reinerswendy ashortdiscussionaboutthesarscov2mrna1273vaccine
AT reidtonyr ashortdiscussionaboutthesarscov2mrna1273vaccine
AT oronskybryan shortdiscussionaboutthesarscov2mrna1273vaccine
AT gruberharrye shortdiscussionaboutthesarscov2mrna1273vaccine
AT reinerswendy shortdiscussionaboutthesarscov2mrna1273vaccine
AT reidtonyr shortdiscussionaboutthesarscov2mrna1273vaccine

Ejemplares similares